Levoxyl Prescription Growth Linked To FDA Levothyroxine Guidance - King
Executive Summary
Prescription growth for King's Levoxyl is related to FDA's July 12 guidance for marketing unapproved levothyroxine products, Exec VP-Corporate Affairs Kyle Macione suggested during a Raymond James healthcare conference call Oct. 2.